Brain Tumor Program

The Neuroscience Institute's Brain Tumor Program is a unique collaboration between the medical center's Neuroscience and Cancer Institutes. The program provides comprehensive services to adults and children with primary brain tumors and metastatic lesions to the central nervous system, as well as complex spinal tumors. Each year, MMC treats hundreds of patients with brain and spinal tumors, including some of the most difficult cases in the state. This is a testament to the experience, expertise, and state-of-the-art technology available here. The program is led by Medical Director Devon Evans, M.D., an oncologist with particular expertise in the care of neuro-oncology patients and Christine Lu-Emerson, M.D., the only board certified neuro- oncologist in the state of Maine.

A multidisciplinary team including medical oncology, neurosurgery, radiation oncology, neuroradiology, pathology, and palliative care work together to tailor treatment plans to the individual patient. These plans take into account the needs of each patient and family while providing high quality care close to home.

Program Highlights

  • Maine's most comprehensive, multidisciplinary team of specialists with expertise in tumors of the brain, spine and central nervous system, including the state’s only Board certified neuro-oncologist, Christine Lu-Emerson, M.D.
  • Outstanding neurosurgical expertise that is unparalleled in the state
  • A coordinated approach to care that also addresses the patient's and family's psychosocial needs
  • A full complement of leading-edge diagnostic and treatment services for adults and children, many of which are not available any place else in Maine
  • Access to novel therapies as part of MMC's ongoing participation in clinical trials
  • Specialized and personalized support for patients and family provided by a neurosciences patient navigator

Conditions Treated

The Neuro-Oncology Program treats some of the most common and rare brain and spinal tumors in both adults and children, including:

  • Anaplastic and low-grade astrocytomas
  • Ependymomas
  • Germinomas
  • Glioblastomas (GBM)/gliosarcomas
  • Mixed malignant gliomas
  • Meningiomas
  • Oligodendrogliomas
  • Primary CNS lymphomas
  • Medulloblastoma
  • Osteosarcoma
  • Ewing's sarcoma
  • Chondrosarcoma

Diagnostic & Treatment Resources

With state-of-the-art technology, our multidisciplinary team has a wealth of diagnostic and treatment resources for patients with brain and spinal tumors:

  • Advanced pre-surgical and intraoperative planning: Our neurosurgeons employ neuro-navigational technology that combines sophisticated imaging techniques and advanced computer software to visualize the brain in three dimensions and determine the precise location of a brain tumor - minimizing risk to surrounding areas of the brain and improving the extent of tumor removal.
  • Stereotactic radio surgery: This procedure allows for precise targeting of brain tumors otherwise unable to be removed with standard operating techniques.
  • Intensity modulated radiation therapy: This technique of radiation treatment allows for higher doses of radiation to the tumor while protecting the surrounding brain tissue.
  • Awake craniotomy with language mapping: This technique can be used in certain cases when a tumor infiltrates brain tissue that affects an essential function such as speech. The patient is fully anesthetized during the opening and closing portions of surgery; after the brain is exposed, the patient is brought into a conscious state and relevant areas of the brain are stimulated to assess for function and pinpoint what tissue can be safely removed.
  • Chemotherapy: A full range of traditional chemotherapeutic agents and targeted molecular therapies are available.
  • Advanced imaging techniques, including MRI perfusion, functional MRI, diffusion weighted imaging, and spectroscopy
  • Embolization: This approach is performed by an interventional neuroradiologist, reduces the blood supply to the cancer, often causing the tumor to shrink and making it easier to treat surgically or with radiation.
  • Clinical Trials: MMC has the largest center for brain tumor research in Maine. Our team works closely with the MMC Research Institute, and we collaborate with Jackson Laboratories. We have patients enrolling in clinical trials, also called research studies, of new treatments that may improve outcomes for them and teach us more about this cancer. Recent or current studies include:
    • Newly diagnosed GBM: Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT promoter Hypermethylation
    • Recurrent GBM: Randomized Phase II Trial of Concurrent bevacizumab and Re-Irradiation Versus bevacizumab Alone as Treatment for Recurrent Glioblastoma
    • Anaplastic Glioma: Phase III Intergroup Study of Temozolomide alone vs. Radiotherapy and concomitant and adjuvant temozolomide vs. Radiotherapy and adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma
    • CNS Lymphoma: Phase II Randmonized Trial to Rituximab, Methotrexate, Procarbazine, Vincristine and Cytarabine +/- Low Dose Whole Brain RT for Primary CNS lymphoma
    • A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)
    • A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation (Alliance A071102)
    • Alliance A071101:  A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
    • Longitudinal Assessment of Neurocognitive Function in Glioma Patients and Identification of Predictive Biomarkers

Clinical Patient Navigator

Brain Tumor Clinical Patient Navigator

Sarah Vreeland, CNRN, M.S.
Phone: (207) 662-1112

Patient Safety During COVID-19

Keeping you safe is our top priority. Learn more about our enhanced safety measures and why you shouldn't delay care.